December 9, 2020
Nutrigenetics, nutrigenomics and phenotypic outcomes of dietary low-dose alcohol consumption in the suppression and induction of cancer development: evidence from in vitro studies
It’s recognized that the consumption of alcoholic drinks could impair genetic and epigenetic regulatory occasions with consequent essential results on cell phenotypes and that its affiliation with chosen genotypes can result in a special threat of most cancers within the inhabitants. The purpose of this evaluate is to select up chosen research on this matter and recapitulate a number of the biochemical and nutrigenetic/nutrigenomic features concerned within the influence of dietary low-dose alcohol consumption on the switching-on or -off of tumorigenic pathways.
These embrace i) the existence of predisposing or protecting human genotypes and the connection between dietary compounds and alcohol within the promotion or inhibition of carcinogenesis; ii) the consequences of different parts of alcoholic drinks within the modulation of the expression of oncogenes and oncosuppressors, the autophagic flux and the onset of apoptosis, with examples of their cytospecificity; and iii) the function of alcoholic beverage consumption inside specific dietary regimens, together with the Mediterranean weight-reduction plan. Taking all the information into consideration, a number of alcohol-associated bioactive dietary compounds seem succesful to modulate peculiar intracellular pathways predisposing to or defending from most cancers. Advances within the nutrigenetic, nutrigenomic and nutriepigenetic information complementing the biochemical and molecular approaches will assist in unveiling their influence on well being final result.
An Epithelial-Mesenchymal Transition-Associated Lengthy Noncoding RNA Signature Correlates With The Prognosis And Development In Bladder Most cancers Sufferers
Bladder most cancers is a typical malignant tumour worldwide. Epithelial-mesenchymal transition (EMT)-related biomarkers can be utilized for early analysis and prognosis of most cancers sufferers. To discover correct prediction fashions is crucial to the analysis and therapy for bladder most cancers. On this research, an EMT-related lengthy noncoding RNA (lncRNA) mannequin was developed to foretell the prognosis of sufferers with bladder most cancers.
Firstly, the EMT-related lncRNAs had been recognized by Pearson correlation evaluation, and a prognostic EMT-related lncRNA signature was constructed by univariate and multivariate Cox regression analyses. Then, the diagnostic efficacy and the clinically predictive capability of the signature was assessed. Lastly, Gene set enrichment evaluation (GSEA) and practical enrichment evaluation had been carried out with bioinformatics. An EMT-related lncRNA signature consisting of was constructed. The diagnostic efficacy of the signature was evaluated by the time-dependent receiver-operating attribute (ROC) curves, through which all of the values of the realm below the ROC (AUC) had been greater than 0.73. A nomogram established by integrating medical variables and the danger rating confirmed that the signature had clinically predict capability.
GSEA evaluation revealed that some cancer-related and EMT-related pathways had been enriched in high-risk teams, whereas immune-related pathways had been enriched in low-risk teams. Useful enrichment evaluation confirmed that EMT was related to considerable GO phrases or signaling pathways. Briefly, our analysis confirmed that the 14 EMT-related lncRNA signature could predict the prognosis and development of bladder most cancers sufferers. To analyze the diagnostic worth of cell-free DNA (cfDNA) and lengthy fragment DNA in breast most cancers sufferers.Feminine sufferers with breast most cancers (n = 80) had been recruited over one 12 months for this research, and served as an remark group. The management group consisted of 50 regular, wholesome females. Plasma ranges of cfDNA and lengthy fragment DNA had been decided a day earlier than therapy, 7 days after therapy, and on the 20th day of therapy. The degrees of cfDNA and lengthy fragment DNA in breast most cancers sufferers earlier than therapy had been considerably greater than these of the management group (p<0.05).
Nutrigenetics, nutrigenomics and phenotypic outcomes of dietary low-dose alcohol consumption in the suppression and induction of cancer development: evidence from in vitro studies
Protosappanin B Exerts Anti-tumor Results on Colon Most cancers Cells by way of Inhibiting GOLPH3 Expression
Protosappanin B (PSB) is a key energetic part of Lignum Sappan extract. Though the antiproliferative results of Lignum Sappan extract have been demonstrated in varied most cancers cells, comparatively little is thought in regards to the results of PSB on tumor development. The purpose of this research was to discover the anti-tumor results of PSB on human colon most cancers cells by regulation of intracellular signaling pathways and Golgi phosphoprotein 3 (GOLPH3) expression in vitro and in vivo. Our outcomes confirmed that PSB successfully inhibited the viability and migration of SW620 cells and induced apoptosis, however had poor impact on HCT116 cells.
 Alpha-bungarotoxin, CF680r |
|||
| 9-00003 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Alpha-bungarotoxin CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Alpha-bungarotoxin CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin |
|||
| 00010-1 | Biotium | 1MG | EUR 168 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
 Fluorescein-Alpha-bungarotoxin |
|||
| 00011 | Biotium | 500uG | EUR 367 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Tetramethylrhodamine-Alpha-bungarotoxin |
|||
| 00012 | Biotium | 500uG | EUR 383 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
) Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
| 00013 | Biotium | 10ST | EUR 417 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
) Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
| 00014 | Biotium | 10ST | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
: (500ug)) Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
| 00015 | Biotium | 500uG | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
: (10x50ug)) Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
| 00016 | Biotium | 10ST | EUR 523 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
 Biotin-xx-a-bungarotoxin |
|||
| 00017 | Biotium | 500uG | EUR 433 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Biotin-cAMP, diisopropylethylammonium salt: |
|||
| 00020 | Biotium | 1MG | EUR 314 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00020-1 | Biotium | 20ST | EUR 418 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
 Biotin-cGMP, diisopropylethylammonium salt: |
|||
| 00021 | Biotium | 1MG | EUR 344 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00021-1 | Biotium | 20ST | EUR 448 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
 Cyanine 644-cAMP: |
|||
| 00022 | Biotium | 1MG | EUR 491 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Cyanine 644-cAMP: (20x50ug) |
|||
| 00022-1 | Biotium | 20ST | EUR 625 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
 Fluorescein Methotrexate, triammonium salt: |
|||
| 00023 | Biotium | 1MG | EUR 281 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
 Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF543 |
|||
| 00026 | Biotium | 500uG | EUR 494 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Rhodamine phalloidin 300u |
|||
| 00027 | Biotium | 300 | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300 |
|||
 Biotin-xx-phalloidin |
|||
| 00028 | Biotium | 100U | EUR 428 |
|
Description: Minimum order quantity: 1 unit of 100U |
|||
 Fluorescein-phalloidin |
|||
| 00030 | Biotium | 300U | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
 Rhodamine 110 phalloidin |
|||
| 00032 | Biotium | 300ST | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300ST |
|||
 Phalloidin) Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
| 00033 | Biotium | 300EU | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300EU |
|||
 Phalloidin, CF405M |
|||
| 00034 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF405M |
|||
| 00034-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 CF488A-cAMP |
|||
| 00036 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 CF640R-cAMP |
|||
| 00037 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Phalloidin, CF555 |
|||
| 00040 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF555 |
|||
| 00040-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF647 |
|||
| 00041 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF647 |
|||
| 00041-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF488A |
|||
| 00042 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF488A |
|||
| 00042-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF543 |
|||
| 00043 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF543 |
|||
| 00043-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF568 |
|||
| 00044 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF568 |
|||
| 00044-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF594 |
|||
| 00045 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF594 |
|||
| 00045-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF633 |
|||
| 00046 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF633 |
|||
| 00046-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF660R |
|||
| 00047 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660R |
|||
| 00047-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF680R |
|||
| 00048 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680R |
|||
| 00048-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF350 |
|||
| 00049 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF350 |
|||
| 00049-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF640R |
|||
| 00050 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF640R |
|||
| 00050-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF532 |
|||
| 00051 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF532 |
|||
| 00051-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF660C |
|||
| 00052 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660C |
|||
| 00052-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF680 |
|||
| 00053 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680 |
|||
| 00053-T | Biotium | 50U | EUR 147 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF430 |
|||
| 00054 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF430 |
|||
| 00054-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF440 |
|||
| 00055 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF440 |
|||
| 00055-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Cholera Toxin Subunit B, CF488A conjugate |
|||
| 00070 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF568 conjugate |
|||
| 00071 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF594 conjugate |
|||
| 00072 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF640R conjugate |
|||
| 00073 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF532 conjugate |
|||
| 00074 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF543 conjugate |
|||
| 00075 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF620R conjugate |
|||
| 00076 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF633 conjugate |
|||
| 00077 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF660R conjugate |
|||
| 00078 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF680R conjugate |
|||
| 00079 | Biotium | 100ug | EUR 282 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Human Transferrin, CF488A conjugate |
|||
| 00081 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF543 conjugate |
|||
| 00082 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF568 conjugate |
|||
| 00083 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF594 conjugate |
|||
| 00084 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF640R conjugate |
|||
| 00085 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF680R conjugate |
|||
| 00086 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF750 conjugate |
|||
| 00087 | Biotium | 1mg | EUR 155 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 HIV-1 tat recombinant antigen |
|||
| 00110-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
 HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
 HIV-1 nef recombinant antigen |
|||
| 00112-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
 HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
 HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
 HCV core recombinant antigen |
|||
| 00115-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
 HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
 HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
 HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
 HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
 HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
 HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
 HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
 HCV NS3 recombinant antigen |
|||
| 00117-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
 HBV core recombinant antigen |
|||
| 00120-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
 HBV core recombinant antigen, Delta |
|||
| 00121-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
 HBV surface recombinant antigen HBsAg |
|||
| 00122-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
 HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
 ORF2 recombinant antigen) HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
 AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
 T, Pallidum recombinant antigen p15 |
|||
| 00141-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
Moreover, PSB considerably decreased the expression of p-AKT, p-p70S6K, β-catenin, and p-ERK1/2 proteins in SW620 cells, and this impact was reversed by the corresponding signaling pathway agonists. Apparently, PSB might additionally suppress expression of SW620 cells in a concentration-dependent method, however SW620 cells transfected with lentiviral vectors overexpressing GOLPH3 can successfully resist the cytotoxic exercise of PSB in vitro. The xenograft experiment of SW620 cells with LV-GOLPH3 confirmed that PSB distinctly inhibited the tumor progress by way of suppressing GOLPH3 expression. Collectively, these findings clarified a brand new anti-cancer mechanism of PSB by inhibition of GOLPH3 expression and intracellular signaling pathways in colon most cancers cells. PSB could also be a possible new drug for colon most cancers.